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Infections caused by multidrug-resistant and extensively drug-resistant Gram-negative bacilli are
increasingly challenging to manage in hospitals and long term-care facilities worldwide. As the
therapeutic options are limited, the International Society of Chemotherapy in collaboration with the
Asia-Pacific Society of Clinical Microbiology and Immunology organised a consensus conference as part
of the 13th Asia-Pacific Congress of Clinical Microbiology and Infection. A panel of international experts
from Europe, the Americas and Asia were convened to discuss the issues of therapeutic options for the
management of these difficult-to-treat pathogens.
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Worldwide antibacterial resistance is increasing dramatically
[1]. The global magnitude of the resistance problem is difficult to
assess. Conflicting definitions regarding combined resistances that
are used by epidemiologists, microbiologists and clinicians have
different implications for surveillance, public health and clinical
case management. As the resistance problem continues to grow,
harmonised definitions with which to describe and classify
bacteria that are resistant to multiple antimicrobial agents are
needed. The European Centre for Disease Prevention and Control
(ECDC) and the US Centers for Disease Control and Prevention
(CDC) published a standardised international terminology to
facilitate grading various antimicrobial resistance profiles and
reporting comparable data [2]. They define:
 multidrug-resistant (MDR) as organisms that are not susceptible
to at least one agent in three or more classes of antibiotics to
which they are usually susceptible (e.g. cephalosporins and b-
lactamase inhibitor combinations, fluoroquinolones and ami-
noglycosides);
 extensively drug-resistant (XDR) as organisms that are suscep-
tible only to one or two classes of antibiotics (mainly polymyxins
and probably tigecycline); and
 pandrug-resistant (PDR) as organisms that are not susceptible to
all known or licensed antibiotics currently available.
The scope of this discussion is confined mainly to organisms
that would be thus classified as XDR, for which there are truly very
few therapeutic options. Typical examples of clinically relevant
and more prevalent XDR Gram-negative pathogens are Pseudomo-
nas aeruginosa, Acinetobacter baumannii and carbapenemase-
producing Enterobacteriaceae (CPE) (mainly Klebsiella pneumoniae
and Escherichia coli). Commonly, such XDR strains carry an
extensive arsenal of unrelated resistance determinants such as
multiple b-lactamase genes (classes A, B, C and D), 16S rRNA
methylase ArmA- and RmtB-encoding genes (affecting all ami-
noglycosides) and dihydrofolate reductase genes (affecting tri-
methoprim), as well as changes in efflux pumps, chromosomally
mediated porin modifications (affecting b-lactams and other
compounds) and modified topoisomerases (affecting quinolones)
[3]. The multidrug resistance pattern is the result of combined
chromosome- and plasmid-encoded mechanisms. Selection may
be caused by a wide range of unrelated antibacterial drugs and
compounds.
Comparing worldwide epidemiological data is complicated
when applying susceptibility/resistance categories defined by
clinical breakpoint values. Such breakpoints may vary depending
on the breakpoint-setting organisation. Although the major
organisations such as the Clinical and Laboratory Standards
Institute (CLSI) and the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) are trying to harmonise their
recommendations, some discrepancies may remain partly related
to the different specific purposes of the guidelines [4]. Both
EUCAST and the CLSI issued breakpoint guidelines in 2011. These
take into account certain mechanisms of resistance, wild-type
population distributions and pharmacokinetic/pharmacodynam-
ics (PK/PD) modelling [5,6]. A detailed discussion of the differences
between the EUCAST and CLSI breakpoints is beyond the scope of
this review but should be considered when comparing and
defining multidrug resistance and extensive drug resistance.
Growing XDR rates among clinically important Gram-negative
bacteria led to increasing usage of last-resort antibiotics, either as
targeted therapy according to bacteriological susceptibility testing
or even as empirical therapy in case of known high XDR rates in aninstitution. Giving a general and global recommendation for
changing empirical choices in response to local XDR rates would
not be feasible and would accelerate the emergence of resistance to
last-resort antibiotics. Every institution should adapt their
empirical regimens according to their own frequently updated
microbiological findings and should carefully balance the decision
with the consequence of increased selection pressure and potential
emergence of resistance without remaining therapy options.
Therefore, for the purposes of this manuscript we focus on
targeted therapy options whilst bearing in mind that these
recommendations can only be based on information garnered
from observational studies, given the absence of randomised
clinical trials. They need to be frequently adapted whenever new
information becomes available.
2. Carbapenems
In general, the use of carbapenems needs to be weighed against
the further selection of organisms that are intrinsically resistant to
carbapenems such as Stenotrophomonas maltophilia or other
important nosocomial pathogens such as meticillin-resistant
Staphylococcus aureus (MRSA) or Candida spp. Moreover, even in
the case of CPE (as discussed below), inappropriate usage of
carbapenems could lead to the selection of increasingly resistant
organisms in the unit or hospital. Although there is a great deal of
reluctance to use carbapenems in the treatment of XDR organisms
if the minimum inhibitory concentrations (MICs) are beyond the
non-susceptible category, there may be a role for carbapenems in
selected situations depending on the MIC and the choice of a
combination partner. There is no clear evidence for the recom-
mendation of carbapenems in such situations, but PK/PD
considerations and preliminary clinical results point to the
usefulness of carbapenems despite being in the non-susceptible
category [7,8]. More clinical data are expected to become available
in the near future.
Using available antibiotics in the setting of MDR and XDR
infections highlights the importance of knowing the MIC value as it
provides vital information beyond the breakpoint categories about
the PD factor (MIC) in the PK/PD balance, especially in severely ill
patients with high PK variability. Considering the MIC rather than
the breakpoint category supports the decision for using a specific
antibiotic as well as for choosing an optimised dosing regimen.
For carbapenems, although there are different MIC breakpoints
as defined by EUCAST and CLSI, it may be possible to achieve a time
above the MIC (T > MIC) for significant proportions of the dosing
interval for organisms with MICs even up to 8 mg/mL. Carbape-
nems display time-dependent bactericidal killing, and significant
efficacy is obtained when free drug concentrations remain above
the MIC for 40–50% of the time between dosing intervals. An
optimised dosing regimen of a carbapenem (e.g. meropenem 2 g
every 8 h or imipenem 1 g every 6 h) with a prolonged infusion
time of ca. 2–3 h each would increase the probability of attaining
the PK/PD target. Meropenem 2 g every 8 h with a prolonged
infusion time of ca. 2–3 h displays a relatively high probability
(85%) for bactericidal target attainment (50% T > MIC) when the
MIC for the infecting organism is up to 8 mg/mL [9].
As the pharmacokinetics of the antibiotics cannot be reliably
predicted in critically ill patients, it would be ideal to perform
therapeutic drug monitoring (TDM) in these patients with XDR or
PDR infections to ensure that the PD targets were indeed achieved
[10]. Regrettably, in most countries, TDM is not routinely available
for b-lactam agents such as carbapenems outside of research
settings. For non-susceptible species with relatively low MICs,
where a carbapenem is used in high doses despite the presence of a
carbapenemase, it may be necessary to monitor concentrations
achieved. On the other hand, if the MIC is >8 mg/mL, the risk of
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are used in combination, so they should not be used as no
substantial benefit can be expected based on the current evidence.
Beyond in vitro data and PK/PD modelling, there is scarce but
growing data on the clinical use of carbapenems in the treatment of
XDR and PDR organisms. Owing to the pressing clinical problem,
more studies are being undertaken and results will hopefully be
available soon. There is no evidence from direct head-to-head
comparisons that meropenem, imipenem or doripenem is signifi-
cantly better than any of the other comparators and thus no
recommendation can be made for any of the three carbapenems in
preference to the others. However, meropenem MICs are generally
lower than imipenem MICs for Gram-negatives—in particular for P.
aeruginosa (but not necessarily A. baumannii)—and this, together
with the good safety profile even at higher doses, may favour
meropenem. Differences in the potential for selection of resistance
reflect subtle variations in the mode of penetration and other
characteristics. The clinical relevance of such differences between
imipenem and meropenem is not clear. There is little, if any,
experience with doripenem dosing regimens beyond 3  1 g daily.
Thus, despite its slightly higher activity against P. aeruginosa there
is no clear preference to its use. However, there is more experience
with the use of meropenem in high-dose and prolonged infusion
regimens, as well as concerns regarding the increased risk of
seizures with high doses of imipenem. With respect to the use of
prolonged or continuous infusion, there are some concerns
regarding the stability of imipenem [11,12]. For a duration of
administration of carbapenems beyond 3 h the stability of
solutions at room temperature need to be considered and strictly
controlled.
3. Aminoglycosides
As aminoglycoside use has declined in many settings,
aminoglycoside resistance has dropped and sometimes aminogly-
cosides are still effective against some XDR strains [13,14]. Owing
to lack of evidence supporting monotherapy in this special patient
population, aminoglycosides should, in general, only be used in
combination because of the risk of the development of resistance
on therapy as well as efficacy concerns [13]. As aminoglycosides
reach high concentrations in the urine, monotherapy appears to be
an option in urinary tract infections (UTIs). Observational data
suggest that these drugs may be superior to polymyxin B or
tigecycline when strictly targeting carbapenem-resistant Klebsiella
sp. in the urine and have been successfully used in a limited
number of patients with UTIs [15].
There are even less data on the appropriate dosage of
aminoglycosides to be used in the treatment of XDR and PDR
organisms. However, given the fact that they are concentration-
dependent antibiotics and that septic patients might have
augmented renal clearance of these drugs, the consensus was to
use dosages on the high side of the dosing range. On the other hand,
the duration of aminoglycoside therapy should be minimised to
the safest level appropriate to reduce the risk of toxicity. PK/PD
modelling suggests that a daily 10 mg/kg dose of gentamicin or
tobramycin provides an 80% probability of response, even for an
MIC of 4.0 mg/mL, with a negligible likelihood of toxicity [16]. As
stated before, the dosage regimen for the individual patient needs
to ensure an adequate drug exposure in this patient in relation to
the MIC and should be re-evaluated according to TDM [17].
4. Colistin
There has been marked renewed interest in this agent as, very
often, XDR organisms are only susceptible to this agent. Colistin fell
out of use because of concerns about nephrotoxicity when bettertolerated antibiotics became available. In recent years, its use has
increased markedly because of the growing incidence of XDR
Enterobacteriaceae, P. aeruginosa and Acinetobacter spp. Despite
the revival of this old drug and usage as a last-resort antibiotic,
colistin has never been subjected to contemporary drug develop-
ment procedures, and major gaps in our knowledge have only just
recently been addressed [18]. Although this agent is reportedly
effective in vitro against most strains of XDR Gram-negative
bacterial infections, the actual clinical outcomes are often
suboptimal, especially when given as a single drug [19,20]. This
is partly due to the severe underlying diseases often associated
with patients infected with XDR bacteria but is also caused by
inadequate dosing regimens that have been employed empirically
for more than 50 years. There are many factors that need to be
taken into account in understanding the PK/PD properties of
colistin, including its complex pharmacokinetics [21]. Colistin, a
mixture of several compounds, is administered as the inactive
prodrug colistimethate sodium (CMS). CMS and colistin have
mixed routes of renal and non-renal elimination, a half-life that
varies between different patient populations, and a volume of
distribution that increases with critical illness. In addition, protein
binding is concentration-dependent. The complex pharmacoki-
netics of colistin have only recently begun to unfold based on
newly developed specific analytical methods. Based on the PK
characteristics, a loading dose to achieve active colistin concen-
trations quickly and a maintenance dosing regimen that is based
on the patient’s kidney function have been proposed. The doses of
CMS used for systemic infections in adults range widely. Based on
recent PK studies, active concentrations at the site of infection can
only be achieved with high dosages. Some recent regimens used
4.5 million International Units (MIU) twice a day or 3 MIU three
times a day after a loading dose of 9 MIU as this might provide a
balance between good clinical effect and acceptable toxicity. On
the other hand, such high doses revive the earlier concerns
regarding renal and neurological toxicity. There is clearly a need for
randomised clinical trials to determine optimal dosing regimens of
colistin in order to optimise clinical outcome, minimise the
development of resistance, reduce toxicity and test optimum
combinations.
Multicentre randomised studies, one funded by the 7th
Framework Program of the European Union (EU) (AIDA-Preserv-
ing Old Antibiotics for the Future) and one clinical study funded by
the US National Institute of Allergy and Infectious Diseases
(NIAID), are underway to compare colistin treatment with a
combination regimen of colistin + carbapenem. Until more
information is available, CMS should be exclusively given to
patients with infections caused by XDR Gram-negative bacteria
susceptible only to colistin. This drug should not be used to treat
infections caused by bacteria susceptible to other antibiotics and
should not be used as a single drug although clinical evidence is
currently scarce [22].
Colistin has been used in a nebulised form for the prevention
and treatment of respiratory tract infections, although the
evidence for this indication outside the cystic fibrosis area is very
limited [23]. Preliminary data in a small series of critically ill
patients with ventilator-associated pneumonia (VAP) caused by
carbapenem-resistant Acinetobacter and K. pneumoniae could not
show superiority of a regimen that included concomitant
inhalation of colistin in addition to intravenous (i.v.) treatment
compared with i.v. treatment alone [24], although it was limited by
small patient numbers and study design issues [25]. The results of
small retrospective studies are conflicting, as demonstrated by
other studies with improved survival with concomitant adminis-
tration of aerosolised and i.v. colistin in patients with VAP [26].
Pooling the data of relevant clinical studies, adjunctive aerosolised
colistin therapy did not reach statistically significant results
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are needed to support such treatment decisions.
Adjunct intrathecal colistin has been used for ventriculitis
caused by XDR organisms but the evidence is largely confined to
case reports [28]. A recent review of 83 episodes of MDR/XDR A.
baumannii ventriculitis/meningitis concluded that intraventricular
or intrathecal administration with concomitant i.v. colistin
represents an important mode of last-resort therapy [29].
5. Tigecycline
There was some optimism initially that tigecycline retained
activity against a portion of XDR Enterobacteriaceae and A.
baumannii, but more recent studies showed only limited useful-
ness of tigecycline in CPE (47% susceptible) with resistance
scattered amongst K. pneumoniae and Enterobacter spp. [30].
Similarly, contemporary isolates from Greece were only suscepti-
ble in 64% of cases for XDR K. pneumoniae and 44% for A. baumannii
[31]. Clinically, the use of tigecycline is limited due to lack of
controlled studies targeting XDR organisms, concerns regarding
efficacy and safety in critically ill patients, as well as the rapid
development of resistance. The emergence of resistance via
upregulation of efflux pumps during therapy is well described
and a matter of concern [32]. The efficacy of tigecycline in clinical
trials is related to low MICs, low baseline albumin concentration,
lower severity and absence of VAP [33], usually not representing
the patient population with XDR infection. Pooling non-inferiority
studies with tigecycline showed excess mortality in critically ill
patients in approved and non-approved indications, prompting a
US Food and Drug Administration (FDA) warning against the usage
of tigecycline when other options are available [34,35]. In addition,
tigecycline is also hampered by low concentrations in the blood
and protein binding of ca. 70% that limits its use in bloodstream
infections [36]. Increasing the dose of tigecycline is not generally
recommended as it is poorly tolerated with increasing risk of
nausea/vomiting related to higher drug exposure and the
consequences of this are not well described [37]. Although
tigecycline monotherapy results in higher failure rates [19,38]
there is, however, some evidence that tigecycline in combination
with colistin and a carbapenem could be effective in the treatment
of severely ill patients with XDR Gram-negative infections. This
remains to be shown in larger prospective studies.
6. Fosfomycin
Fosfomycin is active in vitro against some XDR Gram-negative
bacteria [39] and could be a component of a combination regimen
for the treatment of these infections. The concentrations required
for activity are, however, relatively high for non-fermenters. There
are only a few available data on PK/PD characteristics and clinical
outcomes of fosfomycin [40,41]. Based on in vitro data and PK/PD
modelling, a high dose and prolonged infusion combination
strategy has been suggested [40]. Clinically, doses of 4 g four
times daily and up to 8 g three times daily have been reported
[41,42], but appropriate dosage regimens in XDR situations have
not yet been established.
There are concerns about fosfomycin’s lack of efficacy for A.
baumannii as well as rapid development of resistance in XDR
Gram-negative bacteria (especially P. aeruginosa) during therapy
even when used in combination [43,44]. Fosfomycin should never
be used as monotherapy for severe systemic infections. As the i.v.
form of fosfomycin is not approved in many countries, most
experience is with oral preparations of the agent [42]. This
achieves high concentrations in the urinary tract and has been used
in the treatment of XDR and even PDR UTIs. Fosfomycin’s limitedavailability as an i.v. formulation and missing PK/PD data as well as
clinical information restricts its use in severely ill patients.
7. Use of combination therapy
Combination therapy as a strategy against XDR and PDR micro-
organisms is increasingly being used despite the paucity of clinical
evidence [45,46]. In terms of susceptibility, it should be realised
that susceptibility breakpoints are always based on monotherapy
regimens and are therefore less suitable to use as a predictor for
clinical outcome than usually thought. Exploring combination
therapy, a recent retrospective multicentre study focusing on K.
pneumoniae carbapenemase (KPC)-producing K. pneumoniae
bloodstream infections showed that carbapenems could be
effective in combination with other agents but this did not apply
equally to organisms with an MIC > 8 mg/mL [47]. The authors
concluded that combined treatment with two or more drugs with
in vitro activity against the isolate, especially those also including a
carbapenem, may be more effective than active monotherapy [47].
Similar results of a survival benefit with combination therapy
including a carbapenem were reported by Qureshi et al. [38].
Tzouvelekis et al. compiled the results of 34 small studies involving
a total of 298 patients with either KPC- or metallo-b-lactamase
(MBL)-producing K. pneumoniae [19]. They found that the most
effective regimens were those that included two active agents
including a carbapenem. Combinations of carbapenem with
colistin (5.5% of failures) or with an aminoglycoside (6.2%)
performed significantly better than when these drugs were used
alone or as part of other combinations, whilst combinations of
tigecycline (24% of failures), colistin (32%) and aminoglycosides
(33.3%) in regimens not including a carbapenem exhibited higher
failure rates. On the other hand, the use of tigecycline or colistin as
single active agents resulted in higher failure rates (35.7% and
47.2%, respectively). The superiority of combination therapy is
supported by another recent review on current clinical experience
with carbapenemase-producing Gram-negative bacteria [48].
Clinical evidence for the superiority of combination therapy in
XDR P. aeruginosa infections has not been established yet. The
published meta-analysis did not stratify for the resistance status as
it included mostly studies in the pre-XDR era [49–51]. Also, the
study by Kumar et al. did not focus on XDR P. aeruginosa and does
not provide answers to this clinical question [52]. As few therapy
options exist for XDR P. aeruginosa [53]—usually colistin, less
commonly fosfomycin and aminoglycosides—combination thera-
py appears to be preferable based on non-clinical data of the
abovementioned antibiotics. Clinical data are warranted.
Acinetobacter spp. is increasingly becoming more XDR with few
therapeutic options remaining. Similarly, there are no well
designed clinical trials to compare treatment regimens for such
infections. Most available data are derived from uncontrolled case
series, animal models or in vitro studies. Investigations evaluating
combinations of rifampicin, sulbactam, aminoglycosides, colistin,
carbapenems and other drugs for the management of XDR
Acinetobacter infections have shown conflicting data [54]. A lack
of controlled clinical trials makes it difficult to evaluate the role of
combination therapy for XDR Acinetobacter infection.
Because of the limited activity and rapid emergence of
resistance to colistin, this drug is often propagated as a component
of a combination as mentioned in the carbapenem and tigecycline
sections. Based on the synergism between colistin and other
antibiotics in vitro and in animal studies, a variety of combinations
have been used in the clinical setting and included in uncontrolled
studies or single case series. Besides the combinations of colistin
with carbapenems or tigecycline, combination regimens of
colistin + rifampicin have been widely discussed but the real
clinical benefit still needs to be assessed [55].
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Most research and development (R&D) efforts focus on the
development of new analogues of well known antibacterial classes,
although cross-resistance is already apparent or anticipated
against every one of the new analogues currently in the
development pipeline. Therefore, such modified analogues of
existing antibiotic classes are less likely to be useful for XDR or PDR
pathogens. Similarly, the concept of combining a known cephalo-
sporin or carbapenem analogue with a new b-lactamase inhibitor
(BLI) with extended or narrow b-lactamase coverage appears to
buy some time in the resistance race. The long-known cephalo-
sporin ceftazidime as well as the new cephalosporin analogues
ceftaroline and ceftolozane are being developed in combination
with the old BLI tazobactam or the new BLI avibactam. Avibactam
expands the inhibitory spectrum of tazobactam to include KPC
(class A), class C and some OXA type b-lactamases but not the
rapidly spreading metallo-enzymes (e.g. NDM). XDR Gram-
negatives may have MBLs, upregulated efflux pumps, porin
deficiencies or hyperproduction of extended-spectrum b-lacta-
mases/carbapenemases among their resistance traits. All insur-
mountable hurdles for any BLI! In addition to avibactam, at least
six more BLIs are in development, with considerable gaps in their
activity that remain to be bridged. The phase 3-ready new
aminoglycoside analogue plazomicin overcomes many wide-
spread aminoglycoside-specific resistance mechanisms [56].
Only R&D of new chemical entities unrelated to a known
antibacterial scaffold, not showing cross-resistance to existing
antibacterial drug classes and with a low propensity for emerging
resistance, would be a promising option against XDR strains.
However, very few such R&D programmes are publicly disclosed
and they are not enough to fill the R&D pipelines to increase the
likelihood of novel drugs eventually reaching the patient. Novel
antibiotics without potential cross-resistance with established
drugs and promising activity against XDR bacteria are neither on
the horizon nor anticipated for the near future. Governments in the
USA and EU have initiated several high-level initiatives including a
wide variety of policies and incentives designed to jump start the
development of novel antibacterial drugs and technologies, as
recently reviewed by Theuretzbacher [1,57].
9. Conclusion
Multiresistant Gram-negative bacilli are increasing threats
worldwide. Whilst prevention, antibiotic stewardship and effec-
tive infection control strategies will be paramount in the efforts to
control the emergence and spread of these organisms, novel agents
are urgently needed to treat patients already infected with XDR
and PDR organisms. Right now, we are primarily limited to
combinations of existing agents including polymyxins, aminogly-
cosides, tigecycline, fosfomycin and carbapenems. The latter
agents appear to retain some activity against carbapenemase-
producing organisms when used in combination and for organisms
with MICs up to 8 mg/mL in the majority of patients when
optimised dosing regimens are used. Until newer agents may be
available for clinical use in the far future, the only option is to use
existing agents in a better way, for instance by optimising
exposures and the use of combination therapy [58]. High-quality
randomised clinical trials would provide essential information to
determine the best combination of established antibiotics that can
be used to treat XDR and PDR Gram-negative infections. More
research and practical guidance for individualising dosage regi-
mens based on TDM and clinical decision support systems should
be considered to achieve optimal exposure in critically ill patients.
Presently, evidence-based recommendations on how to optimally
treat critically ill patients with XDR or PDR Gram-negativeorganisms are not possible as clinical data are scarce or missing
altogether. General principles of treatment, such as choosing the
most appropriate antibiotics based on MIC data as well as
considering the individual drug exposure based on TDM, would
help to optimise therapy but may not be available in all
institutions.
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